Member

Vaccinogen


Vaccinogen develops personalized cancer immunotherapies using a patient's own tumor cells, with a stated focus on reducing recurrence after surgery for colon cancer. Its pipeline also includes antibody-based approaches and a proposed liquid biopsy assay.

Industries

N/A

Vaccinogen is currently seeking investment

Vaccinogen is seeking a late-stage investment in the range of 50m-plus

All Investment-seeking Members

Patents

Autologous tumor vaccines and methods

2022-06-07 • US-11351235-B2

View Details

Products

A personalized treatment made from a patient's resected tumor cells and an immune-stimulating adjuvant, intended to reduce cancer recurrence after surgery. The company describes it as being studied for colon cancer.

Antibody candidates derived from B-cell responses observed during treatment research. The company describes potential applications in cancer diagnostics and therapeutics.

Investigational antibody-based candidates intended to direct T cells toward cancer cells expressing cross-reactive antigens.

A proposed cancer screening assay using human monoclonal antibodies; the source describes it as a development goal.

Expertise Areas

  • Cancer immunotherapy
  • Personalized cell-based treatments
  • Colon cancer research
  • Antibody discovery and development
  • Show More (5)

Key Technologies

  • Autologous tumor-cell immunotherapy
  • Bacillus Calmette-Guérin adjuvant
  • Human monoclonal antibodies
  • Bispecific T-cell engagers
  • Show More (3)

Key People

David Oxley

Chief Executive Officer

LinkedIn

Michael G. Hanna, Jr.

Founder and Chief Scientific Officer and former Director of the National Cancer Institute Frederick Cancer Research Center


News & Updates

The company states that the FDA approved its 550-patient pivotal trial protocol and granted Fast Track designation and a Special Protocol Assessment.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.